Levosiz-M Kid Tablet is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated specifically for pediatric use to manage allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, reducing bronchoconstriction, inflammation, and mucus production in the airways. Together, these agents provide a synergistic effect in controlling allergic manifestations and improving respiratory function in children. Levosiz-M Kid Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, as well as asthma prophylaxis in pediatric patients requiring dual therapy. The combination enhances symptom relief, reduces the frequency of asthma exacerbations, and improves overall quality of life. The medication should be administered as per the prescribed dosage, typically once daily in the evening, with or without food. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in those with hypersensitivity to any component. Common adverse effects may include headache, fatigue, and gastrointestinal disturbances. Consultation with a healthcare professional is recommended prior to initiation.